组蛋白去乙酰化酶抑制剂的研究进展

核小体是真核生物染色质的基本单位,通过对组蛋白核心的N-端的乙酰化、甲基化、磷酸化、遍在蛋白化的修饰作用而影响细胞的功能。组蛋白乙酰化酶(histone acetylase HAT)及组蛋白去乙酰化酶(Histone Deacetylases HDAC)之间的动态平衡控制着染色质的结构和基因表达。当组蛋白去乙酰化水平增加,乙酰化水平相对降低,即会导致正常的细胞周期与代谢行为的改变而诱发肿瘤,及神经退行性变。组蛋白去乙酰化酶抑制剂(Histone Deacetylases-inhibitor HDACi)目前是国内外研究的热点。其中,曲古霉素A(Trichostatin A TSA),是最早发现的天然组蛋白去乙酰化酶抑制剂;伏立诺他(Suberoylanilide Hydroxamic Acid SAHA)已经美国FDA批准用于治疗皮肤T细胞淋巴瘤。本文就HDACi分类及其功能出发综述HDACi的作用机制及研究进展。     

Sirtuin1:抗炎治疗新靶点

Sirtuin 1(SIRT1)是组蛋白去乙酰化酶的代表性成员,除可调节代谢、衰老、凋亡外,SIRT1还可通过催化组蛋白及核因子κB(NF-κB)、激活蛋白1(AP-1)等的去乙酰化,从而改变染色质构象、降低转录因子活性、下调炎症基因转录。临床研究已揭示SIRT1在某些炎症性疾病中含量明显降低,而动物实验证实白藜芦醇、SRT1720等SIRT1激活剂可有效减轻炎症损伤。因而,SIRT1有望成为抗炎治疗的新靶点。     

组蛋白去乙酰化酶抑制剂作为放射增敏剂抗肿瘤作用机制研究进展

放射治疗是很多类型的恶性实体肿瘤的标准治疗方法之一,但是放射治疗除了存在一些严重的副作用以外很多恶性肿瘤细胞还具有抵抗放射线的功能,这就导致放射线治疗的局限性以及疗效的减弱。组蛋白超乙酰化作用可以使紧缩的核小体变得松弛,调控细胞凋亡及分化相关基因(Bim and Bmf)的表达,诱导细胞凋亡及分化,增强恶性肿瘤细胞对于放射线的敏感性。组蛋白去乙酰化酶抑制剂可以诱导组蛋白超乙酰化,用于恶性肿瘤的治疗,同时组蛋白去乙酰化酶抑制剂作为放射增敏剂有明显的抗肿瘤作用,并减少放射线治疗的剂量级照射时间,明显减轻放射线引起的副作用。组蛋白去乙酰化酶抑制剂很有可能成为肿瘤分子治疗的新靶点。检索近年来的SCI文章,国内外的学者主要是在蛋白质层面阐述组蛋白去乙酰化酶抑制剂作为放射增敏剂抗肿瘤作用机制,本文首次提出组蛋白去乙酰化酶抑制剂增强放射线促进恶性肿瘤细胞凋亡的特定基因(Bim and Bmf)并结合最新的组蛋白去乙酰化酶抑制剂分类进行综述。     

组蛋白去乙酰化酶4与人类疾病北大核心CSCD

组蛋白去乙酰化酶4(histone deacetylase 4,HDAC4)是一类依赖锌的去乙酰化酶,属于Ⅱ类组蛋白去乙酰化酶(histone deacetylases,HDACs),主要具有去乙酰化酶的活性。HDAC4由去乙酰化酶结构域发挥去乙酰化酶的作用,还具有核定位序列和核输出序列,通过转录后与翻译后水平的修饰可在细胞核和细胞质之间穿梭,进而参与多种调节过程。近年来的研究发现,HDAC4可参与基因的转录调控、细胞凋亡、代谢等诸多生物进程,在多种疾病的发生发展中发挥重要作用。本文主要从HDAC4的结构、去乙酰作用、自身的修饰及其在核浆中的穿梭作用对其进行概述,同时对其在骨关节炎、心血管疾病、肌萎缩性侧索硬化症等不同疾病中的作用、相关的分子机制及组蛋白抑制剂在肿瘤中的应用等方面的研究进展进行综述。     

组蛋白乙酰化／去乙酰化作用与真核基因转录调控

核小体组蛋白的翻译后修饰是真核基因转录调控中的关键步骤。对于组蛋白的这类修饰方式 ,近年来研究最为活跃的是组蛋白Ｎ末端区域保守的Ｌｙｓ上ε ＮＨ 3 的乙酰化作用。随着各种组蛋白乙酰化酶 /去乙酰化酶被克隆、鉴定 ,组蛋白乙酰化 /去乙酰化作用与真核基因转录调控之间的关系也开始逐步得以阐明。1 .真核转录相关的组蛋白乙酰化酶和组蛋白去乙酰化酶1 .1　组蛋白乙酰化酶 (ｈｉｓｔｏｎｅａｃｅｔｙｌｔｒａｎｓ ｆｅｒａｓｅ ,ＨＡＴ)　　核小体组蛋白中Ｎ末端区域上保守的Ｌｙｓ的乙酰化是染色质具有转录活性的标志之一。在组蛋白…     

曲古抑菌素A对体外培养牛成纤维细胞组蛋白乙酰化和甲基化的影响

Trichostatin A(TSA)是一种特异的组蛋白去乙酰化酶抑制剂。研究显示,TSA可以特异地抑制组蛋白去乙酰化酶活性,提高细胞的组蛋白乙酰化水平,激活基因的表达。但是,目前还不是很清楚TSA处理是否对组蛋白甲基化产生影响。本研究以成纤维细胞为研究对象,利用免疫细胞化学技术及激光共聚焦显微镜,探讨了TSA处理体细胞对其组蛋白乙酰化及甲基化修饰的影响。结果显示,随TSA浓度增加,体细胞形态发生明显的改变,细胞变得扁平且核区较大,处理后组蛋白H4K8位点的乙酰化水平随着TSA浓度的增加明显提高。检测组蛋白H3上两个甲基化位点发现,随组蛋白乙酰化水平的增加,H3K4位点的三甲基化（H3K4me3）水平也显著提高。但是,对于H3K9的二甲基化水平（H3K9me2）则没有明显变化。以上结果显示,TSA的处理不仅可以提高体细胞的组蛋白乙酰化水平,同时也增加了与基因表达激活相关组蛋白修饰位点的甲基化水平,但是对于与沉默基因相关的组蛋白修饰位点则没有明显的影响。     

组蛋白去乙酰化酶4与人类疾病

组蛋白去乙酰化酶4（histone deacetylase 4,HDAC4）是一类依赖锌的去乙酰化酶,属于Ⅱ类组蛋白去乙酰化酶（histone deacetylases,HDACs）,主要具有去乙酰化酶的活性。HDAC4由去乙酰化酶结构域发挥去乙酰化酶的作用,还具有核定位序列和核输出序列,通过转录后与翻译后水平的修饰可在细胞核和细胞质之间穿梭,进而参与多种调节过程。近年来的研究发现,HDAC4可参与基因的转录调控、细胞凋亡、代谢等诸多生物进程,在多种疾病的发生发展中发挥重要作用。本文主要从HDAC4的结构、去乙酰作用、自身的修饰及其在核浆中的穿梭作用对其进行概述,同时对其在骨关节炎、心血管疾病、肌萎缩性侧索硬化症等不同疾病中的作用、相关的分子机制及组蛋白抑制剂在肿瘤中的应用等方面的研究进展进行综述。     

组蛋白去乙酰化酶抑制剂(HDAIs)对异染色质的作用

组蛋白乙酰化和去乙酰化可调节染色体的多种功能,例如基因表达和染色体分离等。研究发现,组蛋白去乙酰化酶抑制剂(histone deacetylase inhibitors,HDACIs)可诱导分化、生长阻断和肿瘤细胞凋亡,目前HDACIs正作为抗肿瘤药物进行临床试验,在肿瘤治疗中显示出具有较好的应用前景。然而,人们对于HDACIs在生物体内是如何发挥作用以及不同类型细胞为何会有不同的应答途径却关注甚少。本综述通过讨论HDACIs对周期和非周期细胞中组蛋白去乙酰化酶的抑制结果,来阐明组蛋白乙酰化模式的动力学特征,特别是对基因组异染色质的作用。     

组蛋白去乙酰化酶11的免疫调控功能及其在免疫相关疾病中的作用研究进展

组蛋白乙酰化是一种重要的表观遗传修饰,受到组蛋白乙酰转移酶和组蛋白去乙酰化酶的动态调节。组蛋白去乙酰化酶11 (histone deacetylases 11, HDAC11)是IV类HDAC的唯一成员,能够催化组蛋白和非组蛋白赖氨酸残基去乙酰化并具有去脂酰化活性。HDAC11与免疫细胞的成熟、分化和功能密切相关,多数研究显示HDAC11通过负调控IL-10和上调促炎细胞因子发挥免疫激活作用,但HDAC11也负调控中性粒细胞和T细胞的功能,发挥免疫抑制作用。最近报道HDAC11在炎症反应、肿瘤免疫、移植免疫、自身免疫疾病中发挥重要作用,是免疫治疗的重要靶点。该文就HDAC11的生物学特性、免疫调控功能、在免疫相关性疾病中的作用及其抑制剂开发的最新研究进展作一综述。     

组蛋白去乙酰化酶抑制剂诱导肿瘤细胞凋亡的机制

组蛋白去乙酰化酶抑制剂（HDACi）是一类新的化疗药物,能够有效抑制组蛋白去乙酰化酶的活性,促进组蛋白及非组蛋白的乙酰化修饰,在转录和翻译后修饰水平调控肿瘤靶蛋白及凋亡相关蛋白的表达和降解,活化凋亡信号通路,诱导肿瘤细胞凋亡。HDACi抑制抗氧化蛋白的表达,提高细胞内活性氧的水平,引起细胞的氧化损伤。因此,氧化损伤诱导的细胞凋亡也是HDACi杀伤肿瘤细胞的重要机制。HDACi诱导细胞凋亡机制的发现将进一步促进HDACi在临床治疗中的应用。     

Methods for the analysis of histone H3 and H4 acetylation in blood

LBH589 is one of the many histone deacetylase inhibitors (HDACi) that are currently in clinical trial. Despite their wide-spread use, there is little literature available describing the typical levels of histone acetylation in untreated peripheral blood, the treatment and storage of samples to retain optimal measurement of histone acetylation nor methods by which histone acetylation analysis may be monitored and measured during the course of a patient’s treatment. In this study, we have used cord or peripheral blood as a source of human leukocytes, performed a comparative analysis of sample processing methods and developed a flow cytometric method suitable for monitoring histone acetylation in isolated lymphocytes and liquid tumors. Western blotting and immunohistochemistry techniques have also been addressed. We have tested these methods on blood samples collected from four patients treated with LBH589 as part of an Australian Children’s Cancer Clinical Trial (CLBH589AAU03T) and show comparable results when comparing in vitro and in vivo data. This paper does not seek to correlate histone acetylation levels in peripheral blood with clinical outcome but describes methods of analysis that will be of interest to clinicians and scientists monitoring the effects of HDACi on histone acetylation in blood samples in clinical trials or in related research studies.     

Methods for the analysis of histone H3 and H4 acetylation in blood

LBH589 is one of the many histone deacetylase inhibitors (HDACi) that are currently in clinical trial. Despite their wide-spread use, there is little literature available describing the typical levels of histone acetylation in untreated peripheral blood, the treatment and storage of samples to retain optimal measurement of histone acetylation nor methods by which histone acetylation analysis may be monitored and measured during the course of a patient’s treatment. In this study, we have used cord or peripheral blood as a source of human leukocytes, performed a comparative analysis of sample processing methods and developed a flow cytometric method suitable for monitoring histone acetylation in isolated lymphocytes and liquid tumors. Western blotting and immunohistochemistry techniques have also been addressed. We have tested these methods on blood samples collected from four patients treated with LBH589 as part of an Australian Children’s Cancer Clinical Trial (CLBH589AAU03T) and show comparable results when comparing in vitro and in vivo data. This paper does not seek to correlate histone acetylation levels in peripheral blood with clinical outcome but describes methods of analysis that will be of interest to clinicians and scientists monitoring the effects of HDACi on histone acetylation in blood samples in clinical trials or in related research studies.     

Interferon regulatory factor 1 and histone H4 acetylation in systemic lupus erythematosus

Histone acetylation modulates gene expression and has been described as increased in systemic lupus erythematosus (SLE). We investigated interferon regulatory factor 1 (IRF1) interactions that influence H4 acetylation (H4ac) in SLE. Intracellular flow cytometry for H4 acetylated lysine (K) 5, K8, K12, and K16 was performed. Histone acetylation was defined in monocytes and T cells from controls and SLE patients. RNA-Seq studies were performed on monocytes to look for an imbalance in histone acetyltransferases and histone deacetylase enzyme expression. Expression levels were validated using real-time quantitative RT-PCR. IRF1 induction of H4ac was evaluated using D54MG cells overexpressing IRF1. IRF1 protein interactions were studied using co-immunoprecipitation assays. IRF1-dependent recruitment of histone acetyltransferases to target genes was examined by ChIP assays using p300 antibody. Flow cytometry data showed significantly increased H4K5, H4K8, H4K12, and H4K16 acetylation in SLE monocytes. HDAC3 and HDAC11 gene expression were decreased in SLE monocytes. PCAF showed significantly higher gene expression in SLE than controls. IRF1-overexpressing D54MG cells were associated with significantly increased H4K5, H4K8, and H4K12 acetylation compared to vector-control D54MG cells both globally and at specific target genes. Co-immunoprecipitation studies using D54MG cells revealed IRF1 protein-protein interactions with PCAF, P300, CBP, GCN5, ATF2, and HDAC3. ChIP experiments demonstrated increased p300 recruitment to known IRF1 targets in D54MG cells overexpressing IRF1. In contrast, p300 binding to IRF1 targets decreased in D54MG cells with IRF1 knockdown. SLE appears to be associated with an imbalance in histone acetyltransferases and histone deacetylase enzymes favoring pathologic H4 acetylation. Furthermore, IRF1 directly interacts with chromatin modifying enzymes, supporting a model where recruitment to specific target genes is mediated in part by IRF1.     

组蛋白乙酰化与癌症

由于组蛋白被修饰所引起的染色质结构的改变,在真核生物基因表达调控中发挥着重要的作用,这些修饰主要包括甲基化、乙酰化、磷酸化和泛素化等,其中组蛋白乙酰化尤为重要.组蛋白乙酰转移酶（HAT）和组蛋白去乙酰化酶（HDAC）参与决定组蛋白乙酰化状态.HAT通常作为多亚基辅激活物复合体的一部分,催化组蛋白乙酰化,导致染色质结构的松散、激活转录;而HDAC是多亚基辅抑制物复合体的一部分,使组蛋白去乙酰化,导致染色质集缩,并抑制基因的转录. 编码这些酶的基因染色体易位易于导致急性白血病的发生.另一方面,已经确定了一些乙酰化修饰酶的基因在染色体上的位置,它们尤其倾向定位于染色体的断裂处.综述了HAT和HDAC参与的组蛋白乙酰化与癌症发生之间关系的最新进展,以期进一步阐明组蛋白乙酰化修饰酶的生物学功能以及它们在癌症发生过程中的作用.     

HDAC inhibitor protects chronic cerebral hypoperfusion and oxygen‐glucose deprivation injuries via H3K14 and H4K5 acetylation‐mediated BDNF expression

Vascular dementia (VaD) is the second most common cause of dementia, but the treatment is still lacking. Although many studies have reported that histone deacetylase inhibitors (HDACis) confer protective effects against ischemic and hypoxic injuries, their role in VaD is still uncertain. Previous studies shown, one HDACi protected against cognitive decline in animals with chronic cerebral hypoperfusion (CCH). However, the underlying mechanisms remain elusive. In this study, we tested several 10,11‐dihydro‐5H‐dibenzo[b,f]azepine hydroxamates, which act as HDACis in the CCH model (in vivo), and SH‐SY5Y (neuroblastoma cells) with oxygen‐glucose deprivation (OGD, in vitro). We identified a compound 13, which exhibited the best cell viability under OGD. The compound 13 could increase, in part, the protein levels of brain‐derived neurotrophic factor (BDNF). It increased acetylation status on lysine 14 residue of histone 3 (H3K14) and lysine 5 of histone 4 (H4K5). We further clarified which promoters (I, II, III, IV or IX) could be affected by histone acetylation altered by compound 13. The results of chromatin immunoprecipitation and Q‐PCR analysis indicate that an increase in H3K14 acetylation leads to an increase in the expression of BDNF promoter II, while an increase in H4K5 acetylation results in an increase in the activity of BDNF promoter II and III. Afterwards, these cause an increase in the expression of BDNF exon II, III and coding exon IX. In summary, the HDACi compound 13 may increase BDNF specific isoforms expression to rescue the ischemic and hypoxic injuries through changes of acetylation on histones.